NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080224993

Registered date:23/12/2019

Basic Information

Recruitment status completed
Health condition(s) or Problem(s) studied
Date of first enrollment14/01/2020
Target sample size932
Countries of recruitmentJapan,Asia except Japan,North America,South America,Europe
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : INN of investigational material : pembrolizumab, olaparib, carboplatin, gemcitabine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : pembrolizumab, carboplatin, gemcitabine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcomeefficacy
Secondary Outcomesafety efficacy

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria
Exclude criteria

Related Information

Contact

Public contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation
Scientific contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation